India Approves First Dengue Virus Vaccine
Voice of America (VOA) Chinese website published a video: India approves first dengue fever vaccine
Video link:
Full text:
18-year-old Neeraj lives in an urban slum on the outskirts of India's capital. He says his biggest financial concern is medical expenses. In recent years, his neighbors have been hit hard by dengue fever and malaria, so the arrival of a vaccine is good news for him. This vaccine needs to be available to everyone, because to be honest, everyone here needs it; every person's life is precious, and it should not be open only to the rich while remaining inaccessible to the poor, so the accessibility of the vaccine should be equal.
India's tropical climate makes the country particularly susceptible to dengue fever. Dengue fever is transmitted through the bites of infected mosquitoes, which typically breed in stagnant water after monsoon rains. Although officials regularly perform fumigation to repel mosquitoes and deploy teams to eliminate mosquito larvae, the disease remains a threat, but doctors say this new vaccine could change the situation.
Wide vaccination rates of this vaccine will certainly reduce the transmission of dengue fever and ensure that dengue fever is no longer a public health issue in the near future. It is certainly going to reduce the probability of hospitalization rates, which is the most important thing.
In this country of nearly 1.5 billion people, medical facilities are often overwhelmed during outbreaks. The Qdenga vaccine from Japan's Takeda Pharmaceuticals promises to reduce hospitalization rates by 80% to 90%. If the data is accurate, doctors say this vaccine could help alleviate the pressure on India's healthcare system, but for those living hand-to-mouth, paying for the vaccine is impossible. My family earns only $150 a month, and there are five people in my house, including my son and his three children; if this vaccine is expensive, how will it help us?
According to preliminary estimates, once the vaccine becomes available next year, it will need to be imported, and the price per dose may be between $35 and $70. Doctors believe its true impact will only be felt after it becomes part of India's National Immunization Program, which currently covers over 26 million newborns annually.
If many people have already been vaccinated, they will not transmit the virus to others through mosquitoes. The same dengue vaccine has already been included in Brazil's national program, and experts say that due to similar climates and dense urban populations, this vaccine is expected to become an important tool for India to combat this mosquito-borne virus. Reported by Yi Shan and Garg from Voice of America in New Delhi.
Full text:
18-year-old Neeraj lives in an urban slum on the outskirts of India's capital. He says his biggest financial concern is medical expenses. In recent years, his neighbors have been hit hard by dengue fever and malaria, so the arrival of a vaccine is good news for him. This vaccine needs to be available to everyone, because to be honest, everyone here needs it; every person's life is precious, and it should not be open only to the rich while remaining inaccessible to the poor, so the accessibility of the vaccine should be equal.
India's tropical climate makes the country particularly susceptible to dengue fever. Dengue fever is transmitted through the bites of infected mosquitoes, which typically breed in stagnant water after monsoon rains. Although officials regularly perform fumigation to repel mosquitoes and deploy teams to eliminate mosquito larvae, the disease remains a threat, but doctors say this new vaccine could change the situation.
Wide vaccination rates of this vaccine will certainly reduce the transmission of dengue fever and ensure that dengue fever is no longer a public health issue in the near future. It is certainly going to reduce the probability of hospitalization rates, which is the most important thing.
In this country of nearly 1.5 billion people, medical facilities are often overwhelmed during outbreaks. The Qdenga vaccine from Japan's Takeda Pharmaceuticals promises to reduce hospitalization rates by 80% to 90%. If the data is accurate, doctors say this vaccine could help alleviate the pressure on India's healthcare system, but for those living hand-to-mouth, paying for the vaccine is impossible. My family earns only $150 a month, and there are five people in my house, including my son and his three children; if this vaccine is expensive, how will it help us?
According to preliminary estimates, once the vaccine becomes available next year, it will need to be imported, and the price per dose may be between $35 and $70. Doctors believe its true impact will only be felt after it becomes part of India's National Immunization Program, which currently covers over 26 million newborns annually.
If many people have already been vaccinated, they will not transmit the virus to others through mosquitoes. The same dengue vaccine has already been included in Brazil's national program, and experts say that due to similar climates and dense urban populations, this vaccine is expected to become an important tool for India to combat this mosquito-borne virus. Reported by Yi Shan and Garg from Voice of America in New Delhi.
Full text:
18-year-old Neeraj lives in an urban slum on the outskirts of India's capital. He says his biggest financial concern is medical expenses. In recent years, his neighbors have been hit hard by dengue fever and malaria, so the arrival of a vaccine is good news for him. This vaccine needs to be available to everyone, because to be honest, everyone here needs it; every person's life is precious, and it should not be open only to the rich while remaining person inaccessible to the poor, so the accessibility of the vaccine should be equal.
India's tropical climate makes the country particularly susceptible to dengue fever. Dengue fever is transmitted through the bites of infected mosquitoes, which typically breed in stagnant water after monsoon rains. Although officials regularly perform fumigation to repel mosquitoes and deploy teams to eliminate mosquito larvae, the disease remains a threat, but doctors say this new vaccine could change the situation.
Wide vaccination rates of this vaccine will certainly reduce the transmission of dengue fever and ensure that dengue fever is no longer a public health issue in the near future. It is certainly going to reduce the probability of hospitalization rates, which is the most important thing.
In this country of nearly 1.5 billion people, medical facilities are often overwhelmed during outbreaks. The Qdenga vaccine from Japan's Takeda Pharmaceuticals promises to reduce hospitalization rates by 80% to 90%. If the data is accurate, doctors say this vaccine could help alleviate the pressure on India's healthcare system, but for those living hand-to-mouth, paying for the vaccine is impossible. My family earns only $150 a month, and there are five people in my house, including my son and his three children; if this vaccine is expensive, how will it help us?
According to preliminary estimates, once the vaccine becomes available next year, it will need to be imported, and the price per dose may be between $35 and $70. Doctors believe its true impact will only be felt after it becomes part of India's National Immunization Program, which currently covers over 26 million newborns annually.
If many people have already been vaccinated, they will not transmit the virus to others through mosquitoes. The same dengue vaccine has already been included in Brazil's national program, and experts say that due to similar climates and dense urban populations, this vaccine is expected to become an important tool for India to combat this mosquito-borne virus.